Resource impact statement
No significant resource impact is anticipated
Treosulfan with fludarabine is recommended as an option for conditioning treatment before allogeneic haematopoietic stem cell transplant (alloHSCT) for people with malignant diseases for whom a reduced intensity regimen, such as low-dose busulfan with fludarabine, would be suitable.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or £9,000 per 100,000 population).
This is because the overall incremental cost of treatment is low and the population size is small.
Allogenic stem cell transplant services are commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: